A clinical-stage biotechnology company focused on developing immune-modulating therapies for autoimmune diseases, cancer, and other chronic conditions. Its pipeline includes biologic drug candidates designed to selectively regulate immune responses, with value largely tied to clinical trial outcomes...
3 members of Congress have disclosed 14 trades in Nektar Therapeutics (NKTR), a Healthcare company. The buy/sell breakdown shows 11 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-12-24 | MICHAEL T. MCCAUL | exchange | $1K – $15K |
| 2019-01-10 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2018-06-21 | Josh Gottheimer | sell | $1K – $15K |
| 2018-06-06 | Josh Gottheimer | buy | $1K – $15K |
| 2017-05-25 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2017-02-23 | MICHAEL T. MCCAUL | buy | $15K – $50K |
| 2015-07-31 | Eric Swalwell | sell | $15K – $50K |
| 2015-04-01 | Eric Swalwell | buy | $1K – $15K |
| 2009-11-03 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2009-06-03 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2003-11-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2003-11-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2003-06-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2003-06-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |